Anna Ridderstad Wollberg, born 1965, has over 25 years of experience in pharmaceutical research from both academia as a PostDoc and the pharmaceutical industry, including Astra Zeneca and the Research Institutes of Sweden (RISE). She currently works as Senior Project Leader at SciLifeLab at the University of Uppsala. Anna Ridderstad Wollberg played a key role in the original fractalkine project at Astra Zeneca and was responsible for the preclinical proof-of-concept studies, where KAND567 was selected as a drug candidate. She also had an instrumental role in the tech transfer project to Novakand Pharma. Anna Ridderstad Wollberg holds a PhD in immunology from Stockholm University.
Elected to the board in 2026. Independent in relation to the company and major shareholders.
